ES2619332T3 - Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma - Google Patents

Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma Download PDF

Info

Publication number
ES2619332T3
ES2619332T3 ES13002327T ES13002327T ES2619332T3 ES 2619332 T3 ES2619332 T3 ES 2619332T3 ES 13002327 T ES13002327 T ES 13002327T ES 13002327 T ES13002327 T ES 13002327T ES 2619332 T3 ES2619332 T3 ES 2619332T3
Authority
ES
Spain
Prior art keywords
kits
bone
methods
alkaline phosphatase
directed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13002327T
Other languages
English (en)
Inventor
Philippe Crine
Guy Boileau
Thomas P. Loisel
Isabelle Lemire
Pierre Leonard
Robert Heft
Hal Landy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2619332T3 publication Critical patent/ES2619332T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cereal-Derived Products (AREA)
  • Adornments (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Una composición farmacéutica que comprende un polipéptido que tiene la secuencia expuesta en SEC ID NO: 4 y un soporte farmacéuticamente aceptable que comprende cloruro de sodio y/o fosfato de sodio.
ES13002327T 2007-05-11 2008-05-12 Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma Active ES2619332T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91758907P 2007-05-11 2007-05-11

Publications (1)

Publication Number Publication Date
ES2619332T3 true ES2619332T3 (es) 2017-06-26

Family

ID=40001639

Family Applications (3)

Application Number Title Priority Date Filing Date
ES11004496.3T Active ES2471915T3 (es) 2007-05-11 2008-05-12 Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma
ES13002327T Active ES2619332T3 (es) 2007-05-11 2008-05-12 Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma
ES08757088T Active ES2380546T3 (es) 2007-05-11 2008-05-12 Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES11004496.3T Active ES2471915T3 (es) 2007-05-11 2008-05-12 Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES08757088T Active ES2380546T3 (es) 2007-05-11 2008-05-12 Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma

Country Status (25)

Country Link
US (1) US20100297119A1 (es)
EP (3) EP2158319B1 (es)
JP (1) JP5732603B2 (es)
AT (1) ATE536413T1 (es)
AU (1) AU2008250945B2 (es)
BR (2) BR122019000505B1 (es)
CA (1) CA2687001C (es)
CY (1) CY2016005I2 (es)
DE (1) DE202008018131U1 (es)
DK (3) DK2368999T3 (es)
ES (3) ES2471915T3 (es)
HK (3) HK1162589A1 (es)
HR (1) HRP20140416T1 (es)
HU (2) HUE031655T2 (es)
IL (1) IL202057A0 (es)
LT (1) LTC2368999I2 (es)
LU (1) LU92976I2 (es)
ME (1) ME01828B (es)
NL (1) NL300798I2 (es)
NO (1) NO2016002I2 (es)
PL (3) PL2158319T4 (es)
PT (3) PT2158319E (es)
RS (1) RS53302B (es)
SI (2) SI2368999T1 (es)
WO (1) WO2008138131A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1759001B1 (en) 2004-04-21 2011-04-13 Enobia Pharma Inc. Bone delivery conjugates and method of using same to target proteins to bone
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
US8784833B2 (en) * 2006-06-27 2014-07-22 Saint Louis University Prenatal enzyme replacement therapy for hypophosphatasia
RU2549676C2 (ru) 2007-06-01 2015-04-27 Юниверсити Оф Мэрилэнд, Балтимор СРЕДСТВА НА ОСНОВЕ КОНСТАНТНОЙ ОБЛАСТИ ИММУНОГЛОБУЛИНА СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР
ES2628841T3 (es) 2010-03-12 2017-08-04 Alexion Pharmaceuticals, Inc. Proteínas de fusión npp1
BR112012027765A2 (pt) * 2010-04-30 2019-09-24 Enobia Pharma Inc métodos, composições e kits para tratamento de distúrbios de mineralização da matriz.
CN103154036B (zh) 2010-07-28 2016-05-11 格利克尼克股份有限公司 天然人蛋白片段的融合蛋白以产生有序多聚化免疫球蛋白fc组合物
AU2011350066A1 (en) 2010-12-27 2013-07-11 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
SG11201401605QA (en) 2011-10-19 2014-09-26 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
CN104718223A (zh) 2012-08-20 2015-06-17 格利克尼克股份有限公司 具有抗原结合和多价FCγ受体结合活性的分子
AU2015209783B2 (en) 2014-01-24 2020-10-01 Am-Pharma B.V. Chimeric alkaline phosphatase-like proteins
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
KR20170095278A (ko) 2014-12-05 2017-08-22 알렉시온 파마슈티칼스, 인코포레이티드 재조합 알칼리성 포스파타제를 이용한 발작 치료
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
AU2016308624B2 (en) * 2015-08-17 2022-06-23 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
JP6868617B2 (ja) * 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
US11400140B2 (en) 2015-10-30 2022-08-02 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
WO2017155569A1 (en) * 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
WO2017171871A1 (en) * 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
WO2017173395A1 (en) * 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
EP3436052A4 (en) * 2016-04-01 2019-10-09 Alexion Pharmaceuticals, Inc. TREATMENT OF MUSCLE WEAKNESS USING ALKALINE PHOSPHATASES
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
WO2017214321A1 (en) 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
US20200306350A1 (en) 2016-06-27 2020-10-01 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children and adolescents
JP7018933B2 (ja) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド 気管気管支軟化症の治療方法
JP2020500871A (ja) * 2016-11-30 2020-01-16 パーデュー リサーチ ファウンデーション 副甲状腺ホルモン受容体刺激を介する、骨折をターゲティングした骨再生
MX2019006573A (es) 2016-12-09 2019-11-18 Gliknik Inc Optimizacion de fabricacion de gl-2045 un stradomer multimerizante.
JP7142021B2 (ja) * 2017-03-09 2022-09-26 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質製造プロセス
BR112019020506A2 (pt) 2017-03-31 2020-08-04 Alexion Pharmaceuticals, Inc. métodos para o tratamento de hipofosfatasia (hpp) em adultos e adolescentes
EP3737750B1 (en) 2018-01-09 2024-06-05 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
JP7214962B2 (ja) * 2018-01-17 2023-01-31 東ソー株式会社 アルカリホスファターゼ高発現動物細胞
WO2019183208A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Intestinal alkaline phosphatase formulations
WO2019183209A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
EP3773684A1 (en) 2018-03-30 2021-02-17 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
CN110499285A (zh) * 2018-05-17 2019-11-26 西安组织工程与再生医学研究所 Alpl基因在制备预防和/或治疗低碱性磷酸酶症的产品中的应用
EP4072579A4 (en) * 2019-12-09 2024-05-01 Alexion Pharmaceuticals, Inc. ALKALINE PHOSPHATASE POLYPEPTIDES AND METHODS OF USE THEREOF
CN116848146A (zh) * 2020-09-03 2023-10-03 I·S·Y·陈 可溶性碱性磷酸酶构建体和包含编码可溶性碱性磷酸酶构建体的多核苷酸的表达载体
KR102571967B1 (ko) * 2021-01-21 2023-08-30 주식회사 마라나노텍코리아 Alp 측정용 바이오 센서
MX2023009463A (es) * 2021-02-12 2023-09-21 Alexion Pharma Inc Polipeptidos de fosfatasa alcalina y metodos para su uso.
WO2024050464A2 (en) * 2022-08-31 2024-03-07 University Of Utah Research Foundation Gja1-20k compositions and methods for mitigating ischemia-reperfusion injury

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008A (en) * 1850-01-08 Improvement in alloys for points of lightning-rods
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
CN1263864C (zh) 1993-10-25 2006-07-12 坎吉公司 重组腺病毒载体及其使用方法
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
EP1818407A3 (en) 1999-11-16 2007-08-29 Genzyme Corporation Improved regulatory elements for delivery to the liver
EP1395293B1 (en) 2001-05-14 2009-07-22 Gbp Ip, Llc Lentiviral vectors encoding clotting factors for gene therapy
CA2433479A1 (en) 2002-07-22 2004-01-22 F. Hoffmann-La Roche Ag Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
EP1759001B1 (en) 2004-04-21 2011-04-13 Enobia Pharma Inc. Bone delivery conjugates and method of using same to target proteins to bone
US20070081984A1 (en) * 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
MXPA06014972A (es) 2004-06-23 2007-03-07 Genzyme Corp Metodos y composiciones para el tratamiento de enfermedades poliquisticas.
WO2006039480A2 (en) * 2004-09-29 2006-04-13 The Burnham Institute For Medical Research Tissue non-specific alkaline phosphate (tnap): a therapeutic target for arterial calcification
EP1827502A4 (en) 2004-12-01 2008-01-16 Genzyme Corp PROCESS FOR THE TARGETED DELIVERY OF GENETIC MATERIAL TO THE LIVER

Also Published As

Publication number Publication date
WO2008138131A1 (en) 2008-11-20
PL2662448T3 (pl) 2017-07-31
AU2008250945B2 (en) 2013-12-12
BRPI0811198B8 (pt) 2021-05-25
HK1191372A1 (zh) 2014-07-25
ES2471915T3 (es) 2014-06-27
RS53302B (en) 2014-08-29
EP2158319B1 (en) 2011-12-07
ATE536413T1 (de) 2011-12-15
BR122019000505A2 (pt) 2021-12-14
PT2662448T (pt) 2017-03-29
US20100297119A1 (en) 2010-11-25
JP5732603B2 (ja) 2015-06-10
CY2016005I1 (el) 2016-08-31
PL2158319T3 (pl) 2012-05-31
ES2380546T3 (es) 2012-05-16
CA2687001C (en) 2019-02-12
LU92976I2 (en) 2016-04-11
EP2368999B1 (en) 2014-03-12
HRP20140416T1 (hr) 2014-06-20
JP2010526543A (ja) 2010-08-05
EP2158319A4 (en) 2010-07-21
HK1141047A1 (en) 2010-10-29
NL300798I1 (es) 2016-03-16
BRPI0811198B1 (pt) 2021-03-09
BRPI0811198A8 (pt) 2018-07-31
AU2008250945A2 (en) 2009-12-24
HUS1600005I1 (hu) 2016-02-29
BR122019000505B1 (pt) 2022-01-18
PL2368999T3 (pl) 2014-08-29
AU2008250945A1 (en) 2008-11-20
PT2158319E (pt) 2012-03-06
CY2016005I2 (el) 2016-08-31
NO2016002I2 (no) 2016-02-02
BRPI0811198A2 (pt) 2014-10-21
WO2008138131A9 (en) 2009-08-06
NO2016002I1 (es) 2016-02-02
LTC2368999I2 (lt) 2017-09-25
IL202057A0 (en) 2011-08-01
WO2008138131A4 (en) 2008-12-31
HK1162589A1 (en) 2012-08-31
DK2662448T3 (en) 2017-03-20
EP2158319A1 (en) 2010-03-03
EP2368999A1 (en) 2011-09-28
LTPA2016004I1 (lt) 2016-02-25
EP2662448A1 (en) 2013-11-13
HUE031655T2 (hu) 2017-07-28
PT2368999E (pt) 2014-05-26
DK2158319T3 (da) 2012-03-19
CA2687001A1 (en) 2008-11-20
ME01828B (me) 2014-12-20
DE202008018131U1 (de) 2011-12-30
SI2662448T1 (sl) 2017-05-31
SI2368999T1 (sl) 2014-07-31
DK2368999T3 (da) 2014-05-26
NL300798I2 (es) 2016-03-16
PL2158319T4 (pl) 2016-04-29
EP2662448B1 (en) 2016-12-21

Similar Documents

Publication Publication Date Title
ES2619332T3 (es) Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma
ES2524458T3 (es) DNasa para el tratamiento de la subfertilidad masculina
HRP20090245T1 (en) Pyy agonists and uses thereof
AR031151A1 (es) Articulo absorbente
HUP0300246A2 (en) Delivery system
RS51157B (sr) Baff receptor (bcma), imunoregulatorni agens
SG158141A1 (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
DK1791571T3 (da) Radiofluorinerede peptider
ATE264863T1 (de) 28-epirapaloge
BR0110079A (pt) Combinação de compostos orgânicos
NO2011025I1 (no) Telavancin, eller et farmasøytisk aksseptabelt salt derav, herunder inkludert telavancin hydroklorid
NO20073244L (no) Konjugeringsprodukt
BRPI0417823A (pt) métodos para uso de bifidobactérias probióticas para animais de estimação
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
CU23260B7 (es) PREPARADO FARMACéUTICO DE MOXIFLOXACINA
RS51694B (en) NEW PERINDOPRIL AND PHARMACEUTICAL COMPOSITIONS CONTAINING THERE
JO2578B1 (en) Compounds Theophene benzimidazole
BR0114903A (pt) 7-azaindóis, sua aplicação como inibidores da fosfodiesterase 4 e processos para a sua preparação
ATE537249T1 (de) Wiedergewinnung von gewebefunktion nach verabreichung von b-zellen an verletztes gewebe
ES2422081T3 (es) Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales
UA94231C2 (ru) Олигонуклеотиды или их функциональные гомологи, композиция, которая содержит их, и способ лечения в-клеточной опухоли
MXPA05011783A (es) Peptidos que tienen un efecto inhibidor de enzima convertidora de angiotensina.
DK1200408T3 (da) Vedhæftningsmiddel
RS51534B (en) NEW COMPOUND OF SINUSOID IF CURRENT INHIBITORS AND CALCIUM INHIBITOR AND PHARMACEUTICAL MIXTURE CONTAINED BY IT
ATE410154T1 (de) Pharmazeutische zusammensetzung enthaltend 2,4- dichlorbenzylalkohol und amylmetakresol